ArticleMolecular neurobiology2026
Associations of Insulin Sensitivity with Risk of All-Cause and Cause-Specific Dementia: A Prospective Cohort Study.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Impaired insulin sensitivity has been implicated in neurodegeneration, but whether clinically accessible indices of insulin sensitivity predict dementia risk in the general population remains unclear. We examined associations of the estimated glucose disposal rate (eGDR), a validated marker of insulin sensitivity, with incident all-cause dementia (ACD), Alzheimer's disease (AD), and vascular dementia (VaD), and assessed whether eGDR modifies genetic susceptibility to AD. We included 290,898 dementia-free participants from the UK Biobank. eGDR was calculated using waist circumference, hypertension, and glycated hemoglobin. AD polygenic risk score (AD-PRS) was categorized into tertiles. Longitudinal associations were assessed using Kaplan-Meier (KM) survival analysis and Cox proportional hazards models, with restricted cubic splines employed to examine potential non-linear relationships. Joint effects and interactions between eGDR and AD-PRS were evaluated. The robustness of findings was tested through extensive subgroup and sensitivity analyses. Over a mean follow-up of 13.23 years, 4794 participants developed ACD, 2138 developed AD, and 1070 developed VaD. KM curve revealed that dementia incidence differed significantly across eGDR quartiles (all log-rank P < 0.001). RCS showed significant non-linear inverse associations between eGDR and dementia risk (all P for non-linearity < 0.001). In fully adjusted Cox models, each 1-unit higher eGDR was associated with lower risk of ACD (HR 0.92, 95% CI 0.90-0.94), AD (0.94, 0.92-0.97), and VaD (0.82, 0.78-0.85). Compared with eGDR-Q1, Q4 had lower risks of ACD (HR 0.67), AD (HR 0.70), and VaD (HR 0.42) (all P < 0.001). eGDR modified AD genetic risk (P for interaction < 0.001); participants with low AD-PRS and high eGDR had the lowest AD risk (HR 0.17, 95% CI 0.12-0.23 vs. high AD-PRS and low eGDR group). Findings were consistent across subgroup and sensitivity analyses. Higher eGDR, indicative of greater insulin sensitivity, was associated with reduced risk of incident all-cause and cause-specific dementia, with a significant non-linear inverse dose-response relationship observed. Individuals with both high eGDR low high AD-PRS exhibited the lowest risk of developing AD. These findings suggest that insulin sensitivity may represent a modifiable target for dementia prevention, particularly among individuals with elevated genetic susceptibility.
Indexed as
Identifiers
42470526What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.